LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Doping Agency has welcomed the decision of its country’s government to withhold a payment of 3.6million US dollars (£2.9m) to the World Anti-Doping Agency.The news comes after it emerged last year ...